Induction of liver growth by peroxisome proliferators;Stimulation de la croissance hepatocytaire par les proliferateurs de peroxysomes

Medecine/Sciences

Volumn 15, Issue 12, 1999, Pages 1388-1394

  Chevalier, Stephan ^a   Macdonald, Neil ^a   Chevalier, Nathalie ^b   Roberts, Ruth ^a  

^a SK10 4TJ   (United Kingdom)

^b Armstrong House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; AGRICULTURAL CHEMICAL; CARCINOGEN; CELL NUCLEUS RECEPTOR; CYCLIN DEPENDENT KINASE; CYCLINE; CYTOCHROME P450; FATTY ACID; GROWTH FACTOR; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASTICIZER; RETINOID X RECEPTOR; SOLVENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA REPLICATION; FATTY ACID OXIDATION; GENETIC TRANSCRIPTION; HUMAN; LIVER CANCER; LIVER CELL; MOUSE; NONHUMAN; PEROXISOME; RAT; REVIEW;

EID: 0033371540     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1281     Document Type: Review

References (47)

1. Ashby J, Tennant RW, Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US. NTP. Mutat Res 1991; 257: 229-306.
2. Cattley RC, DeLuca J, Elcombe C, et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pnarmacol 1998; 27: 47-60.
3. Chevalier S, Roberts RA. Perturbation of rodent hepatocyte growth control by non-genotoxic hepatocarcinogens: mechanisms and lack of relevance for human health. Oncol Rep 1998; 5: 1319-27.
4. Pineda Tora I, Gervois P, Staels B. Peroxisome proliferator-activated receptor a in metabolic disease, inflammation, atherosclerosis. Curr Opin Lipidol 1999; 10: 151-9.
5. Latruffe N. Les peroxysomes et la proliferation cellulaire ou la prise en considération d'un organite méconnu. Med Sci 1992; 8: 239-48.
6. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor α. J Natl Cancer Inst 1998; 90: 1702-9.
7. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93.
8. Reddy JK, Rao MS. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res 1989; 214: 63-8.
9. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
10. Lemberger T, Braissant O, Juge-Aubry C, et al. PPAR tissue distribution and interactions with other hormone-signalling pathways. Ann NY Acad Sci 1996; 804: 231-51.
11. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995; 270: 12953-6.
12. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
13. Devchland PR, Keller H, Peters J, Vazquez M, Gonzalez F, Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
14. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleitrophic effects of peroxisome proliferators. Mol Cell Biol 1995; 15: 3012-22.
15. Peters JM, Cattley RC, Gonzalez FJ. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator, Wy-14,643. Carcinogenesis 1997; 18: 2029-33.
16. Aldridge TC, Tugwood JD, Green S. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 1990; 306: 473-9.
17. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. J Biol Chem 1995; 270: 13470-5.
18. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 905-25.
19. Woodyatt N, Lambe K, Myers K, Tugwood J, Roberts, R. The peroxisome proliferator (PP) response element (PPRE) upstream of the human acyl CoA. oxidase gene is inactive in a sample human population: significance for species differences in response to PPs. Carcinogenesis 1999; 20: 369-75.
20. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi A, Reddy J. Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene. J Biol Chem 1998; 273: 30842.
21. Vu-Dac N, Chopin-Delannoy S, Gervois P, et al. The nuclear receptors PPARα and Rev-erb-a mediate the species specific regulation of apolipoprotein Al expression by fibrates. J Biol Chem 1998; 273: 25713-22.
22. Palmer CNA, Hsu M, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor a expression in human liver. Mol Pharmacol 1998; 53: 14-22.
23. Rose ML, Rusyn I, Bojes HK, Germolec DR, Luster M, Thurman RG. Role of Kupffer cells in peroxisome proliferator-induced hepatocyte proliferation. Drug Metab Rev 1999; 31: 87-116.
24. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990; 192: 245-61.
25. Rose ML, Germolec D, Schoonhoven R, Thurman RG. Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis 1997; 18: 1453-56.
26. Bojes HK, Germolec DR, Simeonova P, et al. Antibodies to tumor necrosis factor α prevent increases in cell replication in liver due to the potent peroxisome proliferator WY-14,643. Carcinogenesis 1997; 18: 669-74.
27. Rolfe M, James NH, Roberts RA. Tumour necrosis factor α (TNFα) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis 1997; 18: 2277-80.
28. Hasmall SC, James NH, Macdonald N, Gonzalez FJ, Peters JM, Roberts RA. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARα and TNFα. Mutat Res 1999 (sous presse).
29. Michalopoulos GK, DeFiances MC. Liver regeneration. Science 1997; 276: 60-6.
30. Webber EM, Bruix J, Pierce RH, Fausto N. Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology 1998; 28: 1226-34.
31. bis. Chevalier S, Macdonald N, Roberts RA. Induction of DNA replication by peroxisome proliferators is independent of both tumour necrosis factor a priming activity and EGF-receptor tyrosine kinase activity. J Cell Sci 1999; 112: 4785-91.
32. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Ann Rev Biochern 1998; 57: 443-78.
33. Garcia-Allan C, Loughlin J, Orton T, Lord P. Changes in protein and mRNA levels of growth factor/growth factor receptors in rat livers after administration of phenobarbitone or methylclofenapate. Arch Toxicol 1997; 71: 409-15.
34. Loyer P, Ilyin G, Cariou S, Glaise D, Corlu A, Guguen-Guillouzo C. Progression through Gl and S phases of adult rat hepatocytes. Prog Cell Cycle Res 1996; 2: 37-47.
35. Sherr CJ, Roberts JM. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes Dev 1995; 9: 1149-63.
36. Chevalier S, Chevalier N. Comment mettre en route un cycle de replication de l'ADN chez les eucaryotes? Med Sci 1996; 11: I-IX.
37. Rininger JA, Goldsworthy TL, Babish JG. Time-course comparison of cell cycle protein expression following partial hepatectomy and Wy-14,643-induced hepatic proliferation in F344 rats. Carcinogenesis 1997; 18: 935-41.
38. Gill JH, Brickell P, Dive C, Roberts RA. The rodent non-genotoxic hepatocarcinogen nafenopin suppresses apoptosis preferentially in non-cycling hepatocytes but also elevates CDK4, a cell cycle progression factor. Carcinogenesis 1998; 19: 1743-7.
39. Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ. Role of peroxisome proliferator-activated receptor a in altered cell cvle regulation in mouse liver. Carcinogenesis 1998; 19: 1989-94.
40. Chevalier S, Roberts RA. Gl-arrested FaO cells re-enter the cell cycle upon stimulation with the rodent nongenotoxic hepatocarcinogen nafenopin. Carcinogenesis 1999; 20: 1209-13.
41. Brodsky WY, Uryvaeva IV. Cell ploidy: its relation to tissue growth and function. Int Rev Cytol 1977; 50: 275-332.
42. Styles JA, Kelly M, Pritcharri NR, Elcombe CR. A species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: involvement of the binucleated hepatcyte. Carcinogenesis 1988; 9: 1647-55.
43. Hasmall SC, Roberts RA. Hepatocyte ploidy, nuclearity and distribution of DNA synthesis: a comparison of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens. Toxicol Appl Pharmacol 1997; 144: 287-93.
44. Hasmall S, Roberts RA. The perturbation of apoptosis and mitosis by drugs and xenobiotics. Pharmacol Ther 1999 (sous presse).
45. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
46. James NH, Roberts RA. Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than with suppression of apoptosis. Carcinogenesis 1996; 17: 1623-32.
47. Christensen J, Gonzalez A, Cattley R, Goldsworthy T. Regulation of apoptosis in mouse hepatocytes and alteration of apoptosis by nongenotoxic carcinogens. Cell Growth Diff 1998; 9: 815-25.